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Abstract Reactive oxygen species (ROS) are cellular
signals but also disease triggers; their relative excess
(oxidative stress) or shortage (reductive stress) compared to
reducing equivalents are potentially deleterious. This may
explain why antioxidants fail to combat diseases that cor-
relate with oxidative stress. Instead, targeting of disease-
relevant enzymatic ROS sources that leaves physiological
ROS signaling unaffected may be more beneﬁcial. NADPH
oxidases are the only known enzyme family with the sole
function to produce ROS. Of the catalytic NADPH oxidase
subunits (NOX), NOX4 is the most widely distributed
isoform. We provide here a critical review of the currently
available experimental tools to assess the role of NOX and
especially NOX4, i.e. knock-out mice, siRNAs, antibodies,
and pharmacological inhibitors. We then focus on the
characterization of the small molecule NADPH oxidase
inhibitor, VAS2870, in vitro and in vivo, its speciﬁcity,
selectivity, and possible mechanism of action. Finally, we
discuss the validation of NOX4 as a potential therapeutic
target for indications including stroke, heart failure, and
ﬁbrosis.
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NADPH oxidase inhibitor   NOX4   VAS2870  
NOX4 knock-out
Oxidative stress: the need for validated targets
and therapeutic speciﬁcity
Reactive oxygen species (ROS) have long been suspected
as being ‘bad guys’. They are frequently associated with
the development and progression of chronic, degenerative,
cancerous and inﬂammatory diseases. Indeed an excess of
ROS, i.e. oxidative stress, caused by an imbalance between
ROS production and their removal by antioxidant systems,
may be a common underlying pathogenic mechanism in
these diseases. With the recent additional description of
possible roles of ROS in diverse physiological signaling
processes another form of imbalance deserves attention, i.e.
reductive stress—the excess of reducing agents in a cell
that leads to shortage of ROS. These and other phenomena
[1] may explain the poor outcomes of antioxidant therapies
in clinical studies where even deleterious effects of untar-
geted antioxidant treatment have been reported [2–10].
Rather than attempting to systemically scavenge ROS, it
may be more effective to speciﬁcally target the different
enzymatic sources of pathophysiologically relevant ROS.
Nevertheless, until this has resulted in clinical beneﬁts, the
oxidative stress hypothesis remains unproven.
Several ROS producing enzyme systems exist, including
xanthine oxidase [11], the mitochondrial respiratory chain
[12], lipid peroxidases [13], cytochrome P450 enzymes
[14], and uncoupled endothelial NO synthase [15]. How-
ever, these enzymes produce ROS secondary to their
damage, which can be proteolysis but is often caused by
oxidative stress itself [11, 15]. Thus, there would still be
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123the need to identify this primary source of oxidative stress.
The only enzyme family known to produce ROS as their
primary and sole function are NADPH oxidases. These
multi-protein complexes are comprised of a catalytic,
transmembrane-spanning subunit (NOX), as well as several
structural and regulatory proteins localized in both the
membrane and the cytosol.
The NADPH oxidase family
We are only beginning to understand the enzyme family of
NADPH oxidases, their players and their interaction. The
NOX family consists of seven members, NOX1–5, and two
dual oxidases (Duox), Duox1 and Duox2. Of those, NOX1,
2, 4, and 5 have been implicated in vascular diseases, on
which we focus in this review. All NOX isoforms have six
trans-membrane spanning alpha helices with cytosolic N-
and C-termini. They are differentially expressed and reg-
ulated in various tissues and have different subcellular
localizations, and even different ROS products, i.e. super-
oxide versus hydrogen peroxide (reviewed in [16]). NOX1,
NOX2, and NOX5 appear to produce mainly superoxide
NOX4, mainly H2O2 [17]. All NOX isoforms have been
reported to bind to one or more membrane and/or cytosolic
proteins. p22
phox appears to be a general binding partner for
NOX1-4 in the membrane. NOX1 and 2 also bind the small
GTPase, Rac. Moreover, NOX1 binds the cytosolic sub-
units, NOX organizer 1 (NOXO1) and NOX activator 1
(NOXA1), and NOX2 binds the respective homologues,
p47
phox and p67
phox, and also the cytosolic protein, p40
phox
[18, 19]. NOX4 was reported to bind to the polymerase
(DNA-directed) delta-interacting protein 2 (PolDip2) [20].
In addition to these established NOX binding partners, the
tyrosine kinase substrate with 4/5 SH3 domains (Tks4/5)
[21, 22], and protein disulﬁde isomerase (PDI) were
recently suggested to bind to both NOX1 and 4 [23]. Upon
overexpression in cells, the C-terminus of NOX5 was
shown to interact with Hsp90, which may also bind to
NOX1 and 2 [24]. However, the physiologic relevance of
Fig. 1 The vascular NOX isoform-based NADPH oxidase com-
plexes. Cell or subcellular compartment membranes are shown in
gray, core proteins in yellow, activator binding proteins in green and
organizer binding proteins in blue. All the NOX isoforms shown are
membrane proteins and are localized in the plasma membrane (PM).
Additionally, NOX1 was found at the plasma membrane in caveolae
[147], NOX2 in membranes of phagosomes, and NOX4 in mitochon-
drial [182] and ER-membranes [191], as well as in the nucleus [97].
Little is known about subcellular localization of NOX5 other than the
plasma membrane, but a localization at the ER membrane has been
reported [29, 192]. NOX1, NOX2, and NOX4 are associated with
p22
phox, but only NOX1 and NOX2 are regulated by the small
GTPase Rac. For its activation, the NOX1 enzyme complex requires
the assembly of NOX organiser 1 (NOXO1) and NOX activator 1
(NOXA1), but also forms complexes with p47
phox and p67
phox (not
shown). The NOX2 enzyme complex requires binding of p47
phox,
p67
phox, and optionally p40
phox that can further support the activity. In
contrast to NOX1 and NOX2, NOX4 and NOX5 do not depend on
any of the ‘classical’ cytosolic NADPH oxidase subunits. Recently,
the protein polymerase (DNA-directed) delta-interacting protein 2
(Poldip2) was identiﬁed to bind and to increase the activity of NOX4.
Further, protein disulﬁde isomerase (PDI) [23] and a p47
phox analogue
tyrosine kinase substrate with 4/5 SH3 domains (Tks4/5) have been
reported to bind and activate NOX1 and NOX4 [21, 22]. NOX4 is the
only isoform that produces hydrogen peroxide instead of superoxide
[17]. The NOX5 protein contains four N-terminal calcium-binding
sites that regulate activation of the enzyme. Activity of NOX5 can be
further supported by the binding of Hsp90 or Calmodulin to the
C-terminus of the protein [24]
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123these new potential binding partners for NOX function
needs to be further analyzed (Fig. 1).
With respect to activity regulation, there are funda-
mental differences between the individual NOX catalytic
subunits. Most seem to be dynamically switched on and off
by either regulatory subunits (NOXA1 for NOX1 [25–27],
p67phox for NOX2 [28], and calmodulin for NOX 5 [29,
30]) or intramolecularly by the N-terminal EF hands that
bind free intracellular calcium (NOX5 and Duox1/2 [31]).
In contrast, NOX4 is constitutively active, and modulation
of its expression may thus be a major activity regulator.
The tools to validate the role of NADPH oxidase
in health and disease
During the validation of the involvement of a protein in a
biological process or disease mechanism pharmacological
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Fig. 2 Published NOX4 knock-out (KO) mouse models. a Wild-type
NOX4 has six transmembrane helices and cytosolic binding domains
for FAD and NADPH at the C-terminus. b Deletion of exons 1 and 2
should delete the complete NOX4 protein [32]. c Deletion of exon 4
only leaves the ﬁrst transmembrane domain of NOX4. However,
hypothetically, this may also result in the formation of a splice variant
that contains both FAD and NADPH binding domains and thus has
remaining ROS-forming activity [43]. d Another knock-out was
generated by conditionally deleting exon 9 of NOX4 in cardiomyo-
cytes, thereby deleting the FAD binding domain, likely leaving a non-
functional enzyme [34]. e The fourth published NOX4 KO mouse was
generated by deleting exons 14 and 15 that refer to the NADPH
binding domain. This likely results in the expression of a non-
functional enzyme [33]
The NOX toolbox 2331
123inhibition or genetic deletion are frequently applied. In
addition, speciﬁc antibodies are required to conﬁrm the
expressional regulation of NOX in a given cell or subcel-
lular compartment. With respect to NOX biology these
tools include genetic knock-out [32–35] and transgenic
animals [32, 36, 37], pharmacological inhibitors, and siR-
NAs (see Table 1).
NOX knock-out mouse models
NOX2 knock-out (KO) mice in which exons 2 and 3 are
deleted are commercially available [38], and no other
NOX2 KO model has been published. Two identical NOX1
KO mice carrying a deletion of exons 3–6 have been
published showing a mild hypotensive phenotype and
attenuated angiotensin II-induced hypertension [39, 40].
Unfortunately, no western blot data using tissues of these
mice to conﬁrm the absence or size of a possibly residual
NOX1 protein have been published. An N-terminally
truncated or alternatively spliced NOX1 protein may still
be expressed [41]. However, it is unlikely that NOX1
splice variants lacking the binding sites for regulatory
subunits have any ROS-producing activity. With respect to
NOX4, there is more variety, and four NOX4 KO mouse
models have been published to date (Fig. 2). All differ in
the genetic strategy that was applied to generate them, i.e.
different exons were deleted (exons 1/2, exon 4, exon 9, or
exons 14/15) and constitutive, cell-speciﬁc or inducible
cre/lox systems were used. In future, this may also help to
elucidate the role of alternative splicing in mouse NOX4
biology [32–35]. Indeed, the possibility exists that, at least
in some tissues, the deletion of an early exon may lead to
truncated but active NOX4 variants and thus residual
NOX4 activity. Interestingly, an analogue to the human
NOX4 splice variant D [42] lacking exons 3–11 of murine
NOX4 has been found in kidney and colon. Importantly,
this 28-kDa NOX4 isoform (Fig. 2c) was still capable of
producing ROS, and the authors could blunt this activity by
selective siRNA silencing of this particular isoform [43].
This observation is supported by the ﬁndings that the iso-
lated NOX4 dehydrogenase domain is still able to reduce
substrates like certain artiﬁcial dyes [44]. Although not
shown directly for NADPH oxidases, it is known that ﬂa-
vin-binding domains are able to reduce oxygen, thus
forming superoxide [45, 46]. Accordingly, the residual
NADPH- and ﬂavin-containing protein seems to be sufﬁ-
cient to catalyze ROS formation. Only in mice containing a
deletion of either exon 9 (FAD binding site) or 14/15
(NADPH binding site) is it unlikely that any residual
NOX4 protein could still produce ROS. It is discussed in
the ﬁeld that potential shortened inactive NOX4 proteins
present in exon 9 or exons 14/15 deletions exert dominant
negative or positive effects on other NOX isoforms (e.g.,
NOX1 and NOX2) or NOX binding proteins. For example,
in the absence of NOX4, more free p22
phox may be avail-
able to interact with NOX1/2. Such mechanisms could
affect both the expression and activity of other NOX iso-
forms. However, protein levels of other NOX isoforms
have not been reported to be altered in NOX4 KO mice
[33]. Further, if the activity of other NOX isoforms would
be inﬂuenced these mice would then be expected to show a
mixed phenotype of NOX4 and NOX1 and/or NOX2 KO
mice, e.g. reduced blood pressure and angiotensin II-
induced pressure response (NOX1; [39, 40]) or impaired
oxidative burst activity of circulating neutrophils (NOX2;
[38]). The neutrophil phenotype remains to be analyzed. A
dominant negative regulation of other NOX isoforms in
other cell-types of NOX4 KO cannot be completely ruled
out unless studied. The lack of an effect on blood pressure
by NOX4 deletion in mice [33] argues against such a
hypothetical mixed NOX1/4 phenotype.
Transgenic NOX4 overexpressing mouse models
Parallel to the NOX4 KO mice, three different transgenic
NOX4 (tgNOX4) overexpressing mice have been pub-
lished, two of a cardiomyocyte-speciﬁc manner [32, 36]
and the most recent in an endothelial-speciﬁc manner [37].
Surprisingly, the endothelial tgNOX4 mouse had a lower
systemic blood pressure compared to littermate wild-type
mice, which does not match the vascular phenotype of any
of the NOX4 KO mice, which are all reported to have
unchanged blood pressures [32–34]. Similar to the dis-
cussion above on bystander effects on other NOX isoforms
in NOX4 KO mice, NOX4 overexpression may also affect
both expression and activity of NOX1/2. For example, less
p22
phox may be available to interact with NOX1/2. How-
ever, NOX1 was below detection limits in aortae from both
wild-type and tgNOX4 animals, and NOX2 levels were
unchanged [37]. Thus, dominant negative effects of a
transgenic expression of NOX4 on other NOX isoforms
cannot be excluded, but based on all available data are
unlikely. The discrepancy in blood pressure might be due
to non-physiologically high levels or different subcellular
localization of the overexpressed NOX4 compared to
endogenous NOX4, a general problem of transgenic over-
expression models. A similar subcellular localization of
tgNOX4 and endogenous NOX4 was shown in cardio-
myocytes [32], but no immunoﬂuorescence data in the
endothelium have been published up to date.
siRNA mediated knock-down of NOX4
There are an increasing number of reports using siRNAs
approaches directed against NOX4 (Table 1). Unfortu-
nately, only a few of those siRNAs have been properly
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123validated regarding their overall and NOX isoform speciﬁc-
ity. The necessity for conﬁrming speciﬁcity was impressively
underlined in a recent study [47], which showed that out of
nine tested NOX4-directed siRNAs only six down-regulated
murine NOX4 mRNA levels. Moreover, ﬁve of those six also
down-regulated NOX1 mRNA levels. Another problem with
investigating the role of NOX4 using siRNAs is the lack of
speciﬁc antibodies against NOX4. Many if not all publica-
tions thus rely primarily on the down-regulation of NOX4
mRNA (see Table 1). These reports may need to be
re-evaluated, as it was also recently shown that NOX4 is
highly regulated at the post-transcriptional level, and there-
fore mRNA levels may not necessarily reﬂect protein levels
and ROS formation [48, 49].
Antibodies against NOX
The lack of speciﬁc, freely available and validated anti-
bodies against NOX1 and NOX4 represents one of the
biggest roadblocks in the ﬁeld. As described above, the
validation of both siRNA-mediated down-regulation and
genetic NOX1 and NOX4 KO models depends on the
quality of the antibodies used for the characterization.
Furthermore, as long as the tissue distribution of NOX1
and NOX4 remains unclear, it is very difﬁcult to predict or
estimate speciﬁc versus off-target effects of potential
therapeutic interventions. Several groups and companies
have attempted to generate polyclonal antibodies directed
against different NOX1 and NOX4 peptides or recombi-
nant proteins (Table 2). As these are polyclonal rabbit
antibodies, the access and the amount were always limited.
Also, several different protein sizes have been detected for
NOX4 by different antibodies in the same tissues. This may
be due to unspeciﬁcity of some antibodies, but also caused
by the high sensitivity of the NOX4 protein to lysis
conditions that may result in degradation and dephospho-
rylation [50]. So far, the polyclonal NOX4 antibodies by
the Lambeth and Shah groups are the most frequently used.
Of those antibodies which we have tested for isoform
speciﬁcity, we recommend to use the NOX4 antibody from
the Shah laboratory [51] and our NOX1 antibody [52]. In
2010, the successful generation of the ﬁrst monoclonal
mouse antibodies against human NOX4 was reported [50];
they were used to analyze the tissue distribution, subcel-
lular localization, and structural features of NOX4 [17, 50].
Two of these antibodies (6B11 and 5F9) moderately block
constitutive NOX4 activity in cell-free activity assays [50].
Another monoclonal antibody derived from rabbit is
already commercially available, but no data have been
published using this antibody in tissues and cells other than
monocytes and macrophages [53]. These new antibodies
may be promising and freely available tools for the vali-
dation of NOX1 and NOX4 as a therapeutic target. For
NOX2, the commercially available antibody from Upstate
Technologies (now Millipore, USA) is reliable in our
hands.
Fig. 3 VAS2870 inhibits assembly of NADPH oxidases. NOX1
whole cell homogenates of CaCo-2 cells (native) were prepared and
ROS measured as described in presence or absence of VAS3947
(30 lM) [59]. Columns represent means ± SEM of n = 3 experi-
ments normalized to untreated controls. NOX2 membranes of human
neutrophils, Rac-2-enriched cytosol fraction as well as recombinant
p47
phox and p67
phox were treated with SDS to induce assembly of
these subunits as described [71]. VAS2870 (55 lM) or a solvent
control were added before (pre-) or after (post-) assembly of NOX2
with its subunits, and NADPH oxidase activity was measured using
the cytochome c reduction assay as described [71]. Columns represent
means ± SEM of n = 3 experiments normalized to untreated
controls. NOX4 whole-cell homogenates of A7r5 cells (native),
mainly expressing NOX4 compared to other NOX isoforms, were
prepared and ROS measured as described in presence or absence of
VAS3947 (30 lM) [59]. Columns represent means ± SEM of n C 5
experiments normalized to solvent treated controls. Untransfected
HEK293 cells (not shown) or HEK293 cells stably transfected with
human NOX4 (overexpr.) were treated with VAS2870 or solvent
control, and H2O2 release was measured using Amplex Red. Brieﬂy,
Amplex Red (20 lM) and horseradish peroxidase (100 mU/ml) in a
phosphate buffer containing VAS2870 (10 lM) or equal volumes of
solvent as control were incubated for 10 min at 37 C in the dark in a
96-well plate. Then, 10
5 native or human NOX4 overexpressing
HEK293 cells were added to the wells, and ﬂuorescence was recorded
for 60 min in a Wallac Victor V (Perkin Elmer Life Sciences,
Waltham, MA, USA) or Spectramax M2 (Molecular Devices,
Sunnyvale, CA, USA) plate reader using 540/590 nm excitation/
emission wavelength ﬁlters. Columns represent means ± SEM of the
AUC of time-dependent ﬂuorescence curves in quadruplicates of
n = 4 experiments normalized to non-VAS treated HEK293-NOX4
cells. NOX5 L012 (100 lM) was used to measure NOX5 activity in
HEK293 cells stably transfected with human NOX5 beta. VAS2870
(10 lM) or a solvent control was added to the cells in a 96-well plate,
and basal chemiluminescence was recorded in a Victor V plate reader
with 10 readings per well. Then, NOX5 was stimulated with phorbol
myristate acetate (PMA, 1 lM) and the calcium ionophore ionomycin
(1 lM), or HBSS as control was added (not shown), and chemilu-
minescence was measured for 20 readings per well for 60 min.
Columns represent means ± SEM of AUC of time-dependent
chemiluminescence in quadruplicates normalized to VAS2870 sol-
vent control. (***p\0.001, **p\0.01 are signiﬁcantly different
from control values; n.s. p[0.05 not signiﬁcantly different from
control values; 1-way ANOVA calculated with GraphPad Prism5 for
each individual experiment)
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123Pharmacological NOX inhibitors
An important tool for the validation of potential therapeutic
targets and proof of principle studies is the pharmacolog-
ical inhibition by small chemical compounds. Several
compounds have been used for many years, including
apocynin, diphenylene iodonium (DPI), and 4-(2-amino-
ethyl)-benzensulfonylﬂuorid (AEBSF). However, it has
become apparent that these inhibitors are not speciﬁc for
NOX [1]. Apocynin cannot be used as selective NADPH
oxidase inhibitor due to its direct antioxidant and several
off-target effects [54–57]. DPI is a general ﬂavoprotein
inhibitor, also inhibiting, for example, xanthine oxidase
and eNOS [54, 58, 59], as well as cholinesterases and a
calcium pump [60]. AEBSF is primarily a serine protease
inhibitor [61]. An ideal NOX-inhibitor would have to fulﬁl
several criteria: it should be active in cell-free conditions,
have no intrinsic antioxidant activity, not inhibit other
sources of ROS, and ideally be NOX isoform selective. To
be applied as a tool for target validation, it should be
effective in cells and tissues. For the development into a
therapeutic drug, ADME must permit in vivo application
and toxicity at an acceptable risk-to-beneﬁt ratio. Recently,
several NADPH oxidase-speciﬁc and even isoform-speciﬁc
NOX inhibitors [62–66] have been published; we focus
here on the ﬁrst NADPH oxidase, but not isoform selective
inhibitor, VAS2870 and its analogue VAS3947. For a
detailed overview of the other interesting compounds,
including the highly promising GKT136901, we refer to
other publications [1, 64, 67, 68].
The NADPH oxidase inhibitors VAS2870 and VAS3947
The ﬁrst published inhibitors that resulted from a system-
atic screening effort for selective NADPH oxidase
inhibitors were the triazolo pyrimidines, represented by the
commercially available VAS2870 and its derivatives, such
as VAS3947 [69]. VAS3947 shows an improved solubility
but does not differ in its inhibition proﬁle (unpublished
data). In contrast to formerly used NADPH oxidase
inhibitors, the VAS compounds do not show intrinsic anti-
oxidant activity nor do they inhibit other ﬂavoproteins such
as eNOS and xanthine oxidase [59].
Validation of the VAS compounds
NADPH oxidase inhibition by VAS2870 and VAS3947
was observed in different cell-free assays including whole
cell homogenates of A7r5 (mainly expressing NOX4,
VAS3947 IC50 of 13 lM) and CaCo-2 (mainly expressing
NOX1, VAS3947 IC50 of 12 lM) cell lines [59]. The
ability to inhibit NOX2 can be concluded from experiments
using either intact HL-60 cells (VAS2870 IC50 of 1–2 lM)
or isolated membranes of human neutrophils containing
NADPH oxidase complexes formed from recombinant
cytosolic subunits and NOX2 in the presence of SDS
(VAS2870 IC50 of 10.6 lM) [70, 71]. Furthermore,
NADPH oxidase inhibition by VAS inhibitors could be
detected in various native, i.e. non-overexpressing, cells
expressing different NOX isoforms, including PMA-stim-
ulated human granulocytes (expressing NOX2) [72] and
DMSO-differentiated HL60 cells (mainly expressing
NOX2) [59], several liver carcinoma cell lines [73], ox-
LDL-treated human umbilical vein endothelial cells
(HUVEC) [74], and PDGF-stimulated primary murine
vascular smooth muscle cells [70]. In tissue samples,
VAS2870 inhibits ROS release from aortas of aged spon-
taneous hypertensive rats (SHR) [59]. Also in endothelium-
denuded rat tail arteries [75] and in hypoxic mouse brain
Fig. 4 The role of NOX1, NOX2, and NOX4 in disease models. NO,
generated by NO-synthases (NOS), activates soluble guanylate
cyclase (sGC) by binding to its reduced (Fe
2?) heme moiety leading
to the formation of cGMP from GTP. cGMP mediates protective
effects, e.g. vasodilation and anti-inﬂammation. This signaling
pathway is most likely disturbed by NOX1-derived superoxide
(O2
-) as shown in Angiotensin II-induced hypertension and sponta-
neous hypertensive rats (SHR). Superoxide can either directly interact
with NO to form peroxynitrite or oxidize the essential NOS cofactor
tetrahydrobioapterin (BH4) and thus uncouple NOS. Uncoupled NOS
forms superoxide itself (not shown). Further, superoxide can oxidize
the Fe
2? heme of sGC. Thereby, sGC becomes insensitive to NO.
These mechanisms most likely account, at least in part, for the acute
effects of increased NOX1 activity mediating endothelial dysfunction
and the chronic effects that are discussed to cause hypertension.
NOX2-derived superoxide is a major signaling molecule in innate
immunity mediating host defense. NOX4 is unlikely to directly
interfere with the NO/cGMP-signaling pathway as it releases
hydrogen peroxide (H2O2) and not superoxide. However, in high
concentrations, H2O2 causes acute cytotoxicity. This mechanism is
suggested to be involved in NOX4-mediated effects after acute
ischemic stroke, acute effects of pressure overload in heart, and
bleomycin-induced cytotoxicity. The lower chronic activity of NOX4
seems to be involved in angiogenesis and wound healing, and thus
rather protective
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123slices [33], a signiﬁcant decrease in ROS production was
observed after VAS2870 treatment. In a mouse brain
ischemia reperfusion model, NADPH oxidase activity was
inhibited by in vivo treatment with VAS2870 [33], and in a
zebraﬁsh model of wound healing, DUOX was inhibited by
VAS2870 [76]. In summary, VAS2870 is a well-validated
NADPH oxidase inhibitor, as it shows no intrinsic anti-
oxidant activity, does not inhibit other ﬂavoproteins,
inhibits NADPH oxidase-mediated ROS production in cell
free systems, cells, tissues and in vivo, but it is not NOX
isoform-speciﬁc. Very recently thioalkylation of cysteine
residues of the ryanodine receptor Ca
2? channel (RyR1)
was discovered as a potential off-target effect of VAS2870
in sarcoplasmic reticulum vesicles isolated in glutathione
(GSH) free buffer [193]. The authors also show binding of
VAS2870 to low concentrations of GSH in vitro (10 lM).
It will be interesting to know to which extent thioalkylation
contributes in vivo to the mechanism of action of VAS2870
in the presence of physiological (mM) concentrations of
GSH. However, for further development of the compound
into a drug more extended off-target effects, ADME and
safety data are required, including acute and chronic tox-
icity determination. So far, it has only been shown that
VAS2870 does not inhibit ligand-induced platelet-derived-
growth factor receptor (PDGFR)-tyrosine phosphorylation
or PDGF-dependent phosphorylation of Erk1/2 or Akt [70].
Mechanism of action
In a cell-free system (membranes plus cytosol) VAS2870
only inhibited NOX2 activity when added prior to stimula-
tion of the active complex formation between NOX2 and its
cytosolic partners [71], whereas it showed no effect on
NOX2 activity when added after stimulation of the complex
formation with SDS (Fig. 3). This suggests that VAS2870
inhibits NADPH oxidase complex formation and can inter-
fere with the association of NOX and its binding proteins.
Surprisingly, the activities of NOX4 and NOX5, that are
believed to be independent of cytosolic binding proteins,
were also inhibited by VAS2870 when tested in native,
mainly NOX4-expressing, A7r5 cells and NOX4 or NOX5
overexpressingHEK-293cells,respectively(Fig. 3).Also,in
vivo data suggest that VAS2870 does inhibit NOX4 in native
systems: in a mouse ischemic stroke model, we observed the
same protective effect of VAS2870 in the wild-type as by
deletion of NOX4. VAS2870 exerted no additional protec-
tive effect in NOX4 KO mice [33]. Additionally, in
endothelial cells from wild-type mice, pharmacological
inhibition with VAS2870 or siRNA against NOX4 inhibited
laminar shear stress-induced p38 MAPK activation mediated
by hydrogen peroxide [77], and the effect was the same in
endothelial cells from NOX4 KO mice (Santiago Lamas,
personal communication). Recent data suggest an
intramolecular interaction between unique motifs in C-ter-
minus and cytosolic B-loop of NOX4 that forms a tertiary
structure and activates H2O2 production [78, 79]. An intra-
molecular conformational change may also mediate the
calcium-inducedactivationofNOX5[31].Thus, for all NOX
isoforms, it is possible that inhibition of inter- or intramo-
lecular conformational changes is a common mechanism of
action of VAS2870. Thioalkylation of critical cysteine resi-
dues of NOX enzymes by VAS2870 was recently, e.g. the
cytosolic B-loop, suggested [193], but the molecular details
and binding sites of this remain to be elucidated.
Applying the tools: validated targets and possible
indications
It is still early days in NOX research, and certainly with
respect to translation. Nevertheless, what can already be said
about validated roles of NOX and NADPH oxidase in dis-
ease? And which of these roles may be translated into
therapeutic indications? Different NOX subunits have been
suggested to be implicated in cancer, hypertension, lung
ﬁbrosis,stroke,heartfailure,diabetes,andneurodegenerative
diseases [18]. Several principal ways may be differentiated
by which an excess of ROS leads to pathology: spatially
conﬁned levels of ROS (e.g., in caveolae) that interfere with
nitric oxide’s (NO) vasoprotective signaling, and high levels
(local or systemic) that act, at least in part, independently of
NO and are directly cytotoxic, cause apoptosis (Fig. 4), or
disturb redox-sensitive signaling pathways.
Roles of NOX1, NOX2, and NOX4
NOX2 appears to be relevant in almost every disease
model tested. This may be connected to the role of NOX2
in the innate immune response [80], including to fungal
infections [81, 82] and adaptive immune response at the
level of both T cells and antigen-presenting cells [83, 84].
Thus, in any animal model involving a signiﬁcant inﬂam-
matory response, NOX2 inhibition may lead to an
improvement. Whether this can be exploited in light of the
essential immune functions of NOX2 is an important
question. Importantly, even a small residual NOX2 activity
in X-linked chronic granulomatous disease (CGD) is suf-
ﬁcient for a functional innate immune system [85].
However, it is unknown whether a partial pharmacological
inhibition of NOX2 will sufﬁciently suppress NOX2’s non-
CGD disease-related activity. In addition, chronic NOX2
inhibition might lead to paradoxical autoimmune responses
[86]. Rather, one may want to optimize any NOX inhibi-
tion approach by leaving NOX2 unaffected.
With respect to low and spatially conﬁned ROS over-
production, NOX1 is a good candidate to migrate into
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123caveolae and there cause eNOS uncoupling and endothelial
dysfunction, which is often associated with increased blood
pressure and enhanced platelet aggregation. Moreover, it
may be an early step in the development of atherosclerosis.
Indeed, basal blood pressure [39], angiotensin-induced
hypertension [39, 40], and endothelium-dependent relaxa-
tion in spontaneously hypertensive rats [87] depends—to
some degree—on NOX1. However, whether such chronic
disease indications would ever become realistic for NOX
inhibition is highly questionable unless sophisticated
patient stratiﬁcation biomarkers would become available.
Phosphorylation of vasodilator-stimulated phosphoprotein
(P-VASP) could become such a marker [88].
With respect to higher levels of ROS that act, at least in
part, independently of NO and are directly cytotoxic or
cause apoptosis, NOX4 is well validated. NOX4 is induced
in ischemic stroke, in pressure overload of the heart, and in
a bleomycin model of lung epithelial toxicity resulting in
lung ﬁbrosis. Whilst the interpretation of the stroke data
obtained with NOX4 KO mice is straightforward and was
recently conﬁrmed in a tgNOX4 model of brain ischemia
showing larger infarct sizes [194], the pressure overload
and lung data are less so. In pressure overload, two models
have been applied, proximal aortic or thoracic aortic con-
striction (TAC), and abdominal aortic banding. Both
models differ in the time course by which they affect the
heart. The latter, less acute model allows for angiogenesis
to occur. NOX4 appears to play a double role by contrib-
uting to the cardiomyocyte damage (particularly in the
acute TAC model [32]) and by facilitating subacute angi-
ogenesis and promoting cardiac function (only observable
in the subacute abdominal aortic banding). This may
explain why opposing phenotypes were observed in both
NOX4 KO mouse models and different disease models. In
particular, the TAC model was tested in a cardiomyocyte-
speciﬁc KO and therefore leaves vascular cell-dependent
angiogenesis by deﬁnition unaffected. Thus, NOX4 might
both acutely damage the cardiomyocyte and subacutely
protect the heart by promoting angiogenesis. NOX4 also
promotes angiogenesis in vitro as shown using HUVEC
[89, 90] and ovarian cancer cells [91]. Whether these
effects may be exploited by deﬁning an optimal time
window for NOX4 inhibition in situations of acute heart
failure or by interfering with tumor angiogenesis remains
to be seen, and it needs to be tested by TAC or cancer
models in a global KO animal and by applying NOX
inhibitors. The situation in the lung is similarly compli-
cated. Here, a role of NOX4 in the pathogenesis of hypoxic
pulmonary hypertension was suggested [92], but not con-
ﬁrmed in NOX4 KO mice [33]. Recent data showed that
NOX4 deﬁciency mediated either by NOX4 siRNA [93],
NOX4 inhibition, or NOX4 deletion [35] prevents lung
ﬁbrosis. However, this observation may be model-
dependent as no protection from lung ﬁbrosis was observed
in another NOX4 KO mouse using the same model
(Weissmann N. and Schmidt H.H.H.W., unpublished
observation). Bleomycin induces apoptosis and inﬂamma-
tion in mouse lung epithelial cells [35]. Thus, NOX4 may
be relevant in the bleomycin model, but this model may not
reﬂect the wide spectrum of human lung ﬁbrosis (idio-
pathic, radiation, silicosis, systemic lupus erythematosus,
dermatomyositis, sclerodermia, rheumatoid arthritis,
pneumoconiosis, acute respiratory distress syndrome,
chronic heart failure, drug-induced). Thus, a model-inde-
pendent role of NOX4 in lung ﬁbrosis needs to be tested in
different models of the disease. Even then, the clinical chal-
lenge of a life-long therapy with a NOX4 inhibitor would
remain. Importantly, all published NOX4 KO models lack a
basal phenotype. This is an important observation for the
characterization of NOX4 as a therapeutic target, as it indi-
cates that NOX4 inhibition would probably not cause severe
complications. The situation may be different when co-mor-
bidities occur and protective roles of NOX4 may well cause
side effects. From the current state of knowledge, such
potential side effects of sub-chronic and chronic NOX4
inhibition could arise from decreased angiogenesis.
In conclusion, according to the current knowledge, acute
ischemic stroke appears to be one of the most promising
and safest targets for NOX inhibition. It evades the risk of
chronic therapy and the rather double-edged role of NOX4
in heart failure and angiogenesis. Nevertheless, speciﬁc,
isoform-selective NOX inhibitors and reliable, freely
available antibodies will be key in elucidating the full
therapeutic potential of NOX in species other than mouse
and in different disease models.
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